Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti A Patel ,Eytan M Stein,Christopher R Cogle,Tibor Kovacsovics,Leonard Rosenberg,Tara L Lin,James M Foran,Nyla A Heerema,Mona Stefanos,Uma Borate,Rebecca L Olin,Alice S Mims,Ross L Levine,Maria R Baer,Sonja Marcus,Mark R Litzow,Abigail B Shoben,Amy Burd,John C Byrd,William Blum,Gary J Schiller,Franchesca Druggan,Amy S Ruppert,Wendy Stock,Matthew C Foster,Robert L Redner,Theophilus J Gana ,Ashley Owen Yocum ,Brian J Druker ,Zeina Al‐Mansour ,Timothy Chen ,Ronan T Swords ,Jo‐Anne Vergilio ,Robert H Collins ,Martha Arellano ,Michael Boyiadzis

doi:10.1182/blood-2021-149115

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti A Patel , Eytan M Stein + Show 34 more

Open Access

https://doi.org/10.1182/blood-2021-149115

Copy DOI

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.